{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n FLJ16779 is a long non‐coding RNA that has been identified as a component of a prognostic signature for gastric cancer. In a recent study, FLJ16779, together with OVAAL and FAM230D, was incorporated into a three‐lncRNA model that robustly stratified patients into high- and low-risk groups, with elevated risk scores being associated with significantly poorer overall survival (OS) (1."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": " Gene Set Enrichment Analysis further indicated that the low-risk group, which may reflect differential lncRNA expression including FLJ16779, exhibited significant clustering of diverse metabolic pathways, implicating these lncRNAs in the modulation of metabolic processes that could underlie gastric carcinogenesis (1."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": " Although the precise mechanistic role of FLJ16779 remains to be fully elucidated, its inclusion in the prognostic signature highlights its potential as an independent biomarker for the prediction of patient outcomes in gastric cancer.\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Yongqiang Wang, Huimin Zhang, Ju Wang "}, {"type": "b", "children": [{"type": "t", "text": "Discovery of a novel three-long non-coding RNA signature for predicting the prognosis of patients with gastric cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Gastrointest Oncol (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.21037/jgo-20-140"}], "href": "https://doi.org/10.21037/jgo-20-140"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "32953159"}], "href": "https://pubmed.ncbi.nlm.nih.gov/32953159"}]}]}]}